www.ultragenyx.com Open in urlscan Pro
138.91.252.236  Public Scan

Form analysis
0 forms found in the DOM

Text Content

USA English
Brazil Português
Canada English Français
Japan Japanese
 * Blog
 * Patient Resources
 * Investors & Media
 * Careers
 * Contact

 * Our Purpose
   * Our Commitment to Patients
     * Rare Disease Day
   * Supporting Access for Patients
     * Approved Medicines
     * Investigational Therapies
     * Patient/Advocacy Resources
   * Corporate Sustainability
     * Grants and Charitable Contributions
 * Our Company
   * Our Leaders
   * Our Partners
   * Contact Us
 * Our Medicines
   * Crysvita® (burosumab-twza)
   * Dojolvi® (triheptanoin)
   * Mepsevii® (vestronidase alfa—vjbk)
 * Our Research
   * Our Science
   * Our Pipeline
     * DTX401 for GSDIa
     * DTX301 for OTC
     * UX701 for Wilson Disease
     * UX143 for Osteogenesis Imperfecta
     * GTX-102 for Angelman Syndrome
     * UX053 for GSDIII
     * Our Clinical Trial Transparency Commitment
     * UX111 for MPS IIIA
   * Our Gene Therapy Platform

 * Blog
 * Patient Resources
 * Investors & Media
 * Careers
 * Contact


MENU


LEADING THE FUTURE OF RARE DISEASE MEDICINE FOR PATIENTS LIKE MASON.

Learn More

If you have any difficulty using our website and need an accommodation due to a
disability, you may contact us at: (888) 384-0599

We use our experience, insight, and commitment to move the rare disease
community forward.

Our goal is to provide medicines to those with limited options and to help
patients face rare diseases head on, with courage and confidence.

Press Releases

Ultragenyx has acquired GeneTx to continue to advance development of GTX-102 for
Angelman Syndrome. You can read more

here.
Pipeline

Our diverse portfolio of approved medicines and investigational therapies is
advancing first- or best-in-class treatments for diseases that exhibit a clear
biology for treatment and are severely underserved by current standard of care.

Learn more   
Culture

We maintain an environment that puts people first. This includes patients, their
families and caregivers, and our employees. We respect the responsibility that
comes with developing medicines for rare diseases.

Learn more   


LATEST ANNOUNCEMENTS

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 4, 2022

Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

September 9, 2022

Ultragenyx to Participate at Citi BioPharma Conference

September 1, 2022

Read More News


COVID-19 INFORMATION

As the COVID-19 pandemic continues to evolve, we are focused on the health and
safety of our community including patients, caregivers, healthcare providers,
partners, and employees. For patients specifically, this means that we are
committed to providing an uninterrupted supply of our medicines to the patients
who rely on them.

Learn More

 * Our Purpose
   * Our Commitment to Patients
   * Supporting Access for Patients
   * Corporate Sustainability
 * Our Company
   * Our Leaders
   * Our Partners
   * Contact Us
 * Our Medicines
   * Crysvita® (burosumab-twza)
   * Dojolvi® (triheptanoin)
   * Mepsevii®(vestronidase alfa—vjbk)
 * Our Research
   * Our Science
   * Our Pipeline
   * Our Gene Therapy Platform
 * Careers
   * Culture
   * Benefits
   * Talent Network
   * Emerging Talent
   * Jobs
 * Investors & Media
   * Press Releases
   * Events & Presentations
   * Governance
   * SEC Filings
   * Stock Information
   * Analyst Coverage
   * Investor FAQ

Our Other Websites
 * www.UltraRareAdvocacy.com
 * www.UltraCareSupport.com

 * 
 * 

©2021 Ultragenyx Pharmaceutical. All rights reserved.

 * Privacy Policy
 * Cookie Policy

This site uses cookies to provide you with a more responsive and personalized
service. By clicking "Accept" below, you agree to the use of cookies on this
site. Please read our Cookie Policy and Privacy Policy for more information on
the use of cookies on this website.
Accept Do not accept

You are now leaving the Ultragenyx U.S. Website

You are leaving the Ultragenyx U.S. website and being redirected to another
Ultragenyx website outside of the U.S. The information on Ultragenyx websites
outside of the U.S. is only appropriate for residents of the selected country
website.

Cancel Continue